Capricor Therapeutics, Inc. (CAPR)

NASDAQ: CAPR · Real-Time Price · USD
12.19
+0.60 (4.88%)
Jun 17, 2025, 4:00 PM - Market closed
4.88%
Market Cap 557.18M
Revenue (ttm) 17.36M
Net Income (ttm) -55.06M
Shares Out 45.71M
EPS (ttm) -1.42
PE Ratio n/a
Forward PE 45.57
Dividend n/a
Ex-Dividend Date n/a
Volume 2,559,013
Open 12.12
Previous Close n/a
Day's Range 11.57 - 13.51
52-Week Range 3.52 - 23.40
Beta 0.85
Analysts Strong Buy
Price Target 40.14 (+229.29%)
Earnings Date Aug 6, 2025

About CAPR

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 160
Stock Exchange NASDAQ
Ticker Symbol CAPR
Full Company Profile

Financial Performance

In 2024, Capricor Therapeutics's revenue was $22.27 million, a decrease of -11.55% compared to the previous year's $25.18 million. Losses were -$40.47 million, 81.6% more than in 2023.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for CAPR stock is "Strong Buy." The 12-month stock price forecast is $40.14, which is an increase of 229.29% from the latest price.

Price Target
$40.14
(229.29% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program

SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare disea...

23 hours ago - GlobeNewsWire

Capricor: A Hold Rating With Regulatory FDA Form Given For Deramiocel Advancement

I am downgrading Capricor Therapeutics, Inc. stock from Strong Buy to Hold due to FDA Form 483 risks from a Pre-License Inspection of its manufacturing facility. While deramiocel's clinical data for D...

6 days ago - Seeking Alpha

Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program

SAN DIEGO, June 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare disea...

6 days ago - GlobeNewsWire

Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Com...

14 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Com...

15 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Connect

NEW YORK CITY, NY / ACCESS Newswire / June 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Com...

16 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / May 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Com...

18 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Stockholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Com...

19 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Capricor Therapeutics, Inc. (CAPR) and Encourages Investors to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Com...

20 days ago - Accesswire

Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Com...

21 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Connect

NEW YORK CITY, NY / ACCESS Newswire / May 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Com...

22 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Investors to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Com...

25 days ago - Accesswire

Capricor Therapeutics' Buy Thesis Ahead Of Deramiocel PDUFA Date

Capricor Therapeutics basically has two platforms: Deramiocel CDC therapy and the StealthX exosome platform. However, its flagship candidate is undoubtedly Deramiocel, which has so far secured a PDUFA...

26 days ago - Seeking Alpha

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Com...

26 days ago - Accesswire

Capricor: High-Reward DMD Treatment Bet With Strong Data And Looming FDA Decision

Capricor's lead asset, deramiocel, targets DMD-related cardiomyopathy and faces key FDA milestones (ADCOM, PDUFA) in 2025. A strong cash position and partnership with Nippon Shinyaku provide financial...

27 days ago - Seeking Alpha

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Stockholders to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Com...

27 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Stockholders to Connect

NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Com...

4 weeks ago - Accesswire

I Missed The Quantum Rally - I Won't Miss The Next One

Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, progra...

4 weeks ago - Seeking Alpha

CAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES , May 20, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Capricor Therapeutics...

4 weeks ago - PRNewsWire

Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Com...

4 weeks ago - Accesswire

Capricor Therapeutics, Inc. (CAPR) Q1 2025 Earnings Conference Call Transcript

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marban - Chief Executive Officer ...

5 weeks ago - Seeking Alpha

Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13

SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseas...

6 weeks ago - GlobeNewsWire

US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy

Capricor Therapeutics said on Monday the U.S. Food and Drug Administration (FDA) plans to convene a panel of outside experts before deciding on the company's cell therapy for a heart condition related...

6 weeks ago - Reuters

Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

-Company remains on track for PDUFA target action date of August 31, 2025- -Advisory committee meeting to be held in advance of target action date-   SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) --   Capr...

6 weeks ago - GlobeNewsWire

Capricor Therapeutics, Inc. (CAPR) Q4 2024 Earnings Call Transcript

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marban - Chief Executive Office...

3 months ago - Seeking Alpha